

Literaturverzeichnis zum Beitrag Nichtalkoholische Fettlebererkrankung Druckpunkt 4-2017

1. Abu-Shanab A, Quigley MM. The role of the gut microbiota in nonalcoholic fatty liver disease. *Nat Rev Gastroenterol Hepatol* 2010; 7: 691-701.
2. Adams LA, Lymp JF, Sauver JS, Sanderson SO, Lindor KD, Feldstein A, Angulo P. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. *Gastroenterology* 2005; 129: 113-121.
3. Amar J, Burcelin R, Ruidavets JB, Cani PD, Fauvel J, Alessi MC, Chamontin B, Ferrières J. Energy intake is associated with endotoxemia in apparently healthy men. *Am J Clin Nutr* 2008; 87: 1219-1223.
4. Ascha MS, Hanouneh IA, Lopez R, Tamimi TAR, Feldstein AF, Zein NN. The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. *Hepatology* 2010; 51: 1972-1978.
5. Assy N, Kaita K, Mymin D, Levy C, Rosser B, Minuk G. Fatty Infiltration of liver in hyperlipidemic patients. *Dig Dis Sci* 2000; 45: 1929-1934.
6. Bhatia LS, Curzen NP, Calder PC, Byrne CD. Non-alcoholic fatty liver disease: a new and important cardiovascular risk factor? *Eur Heart J* 2012; 33: 1190-2003.
7. Browning J, Szczepaniak L, Dobbins R, Nuremberg P, Horton J, Cohen J, Grundy S, Hobbs H. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. *Hepatology* 2004; 40: 1387-95.
8. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. *Am J Gastroenterol* 1999; 94: 2467-2474.
9. Buechler C, Wanninger J, Neumeier M. Adiponectin, a key adipokine in obesity related liver diseases. *World J Gastroenterol* 2011; 17: 2801-2811.
10. Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, Charlton M, Sanyal AJ. The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. *Hepatology* 2012; 55: 2005-2023.
11. Demir M, Lang S, Nierhoff D, Drebber U, Hardt A, Wedemeyer I, Schulte S, Quasdorff M, Goeser T, Töx U, Steffen HM. Stepwise combination of simple noninvasive fibrosis scoring systems increases diagnostic accuracy in nonalcoholic fatty liver disease. *J Clin Gastroenterol* 2013; 47: 719-726.
12. Dowman JK, Tomlinson JW, Newsome PN. Systematic review: the diagnosis and staging of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. *Aliment Pharmacol Ther* 2011; 33: 525-540.

13. Dunn W, Xu R, Schwimmer JB. Modest wine drinking and decreased prevalence of suspected nonalcoholic fatty liver disease. *Hepatology* 2008; 47: 1947-1954.
14. Dunn W, Xu R, Wingard D, Rogers C, Angulo P, Younossi Z, Schwimmer J. Suspected nonalcoholic fatty liver disease and mortality risk in a population-based cohort study. *Am J Gastroenterol* 2008; 103: 2263-2271.
15. Ekstedt M, Franzen LE, Mathiesen UL, Thorelius L, Holmqvist M, Bodemar G, Kechgias S. Long-term follow-up of patients with NAFLD and elevated liver enzymes. *Hepatology* 2006; 44: 865-873.
16. European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD) and European Association for the Study of Obesity (EASO). EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. *J Hepatol* 2016; 64: 1388-1402
17. Fassio F, Alvarez E, Dominguez N, Landeira G, Longo C. Natural history of nonalcoholic steatohepatitis: a longitudinal study of repeat liver biopsies. *Hepatology* 2004; 40: 820-826.
18. Georgescu EF, Ionescu R, Niculescu M, Mogoanta L, Vancica L. Angiotensin-receptor blockers as therapy for mild-to-moderate hypertension-associated non-alcoholic steatohepatitis. *World J Gastroenterol* 2009; 15: 942-954.
19. Hallsworth K, Fattakhova G, Hollingsworth KG, Thoma C, Moore S, Taylor R, Day CP, Trenell MI. Resistance exercise reduces liver fat and its mediators in non-alcoholic fatty liver disease independent of weight loss. *Gut* 2011; 60: 1278-1283.
20. Harrison SA, Torgerson S, Hayashi PH. The natural history of nonalcoholic fatty liver disease: a clinical histopathological study. *Am J Gastroenterol* 2003; 98: 2042-2047.
21. Henao-Mejia J, Elinav E, Jin C, Hao L, Mehal WZ, Strowig T, Thaïss CA, Kau AL, Eisenbarth SC, Jurczak MJ, Camporez JP, Shulman GI, Gordon JI, Hoffman HM, Flavell RA Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. *Nature* 2012; 482: 179-185.
22. Hernaez R, Lazo M, Bonekamp S, Kamel I, Brancati FL, Guallar E, Clark JM. Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: a meta-analysis. *Hepatology* 2011; 54: 1082-1090.
23. Kau AL, Ahern PP, Griffin NW, Goodman AL, Gordon JI. Human nutrition, the gut microbiome and the immune system. *Nature* 2011; 474: 327-36.
24. Kistler KD, Brunt EM, Clark JM, Diehl AM, Sallis JF, Schwimmer JB for the NASH CRN Research Group. Physical activity recommendations, exercise intensity, and histological severity of nonalcoholic fatty liver disease. *Am J Gastroenterol* 2011; 106: 460-468.

25. Kleiner DE, Brunt EM, van Natta M, Behling C, Contos M, Cummings OW, Ferrell LD, Liu YC, Torbenson MS, Unalp-Arida A, Yeh M, NcCullough AJ, Sanyal AJ for the Nonalcoholic Steatohepatitis Clinical Research Network. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. *Hepatology* 2005; 341: 1313-1321.
26. Lau K, Lorbeer R, Haring R, Schmidt CO, Wallaschofski H, Nauck M, John U, Baumeister SE, Völzke H. The association between fatty liver disease and blood pressure in a population-based prospective longitudinal study. *J Hypertens* 2010; 28: 1829-1835.
27. Lavine JE, Schwimmer JB, van Natta ML, Molleston JP, Murray KF, Rosenthal P, Abrams SH, Scheimann AO, Sanyal AJ, Chalasani N, Tonascia J, Unalp A, Clark JM, Brunt EM, Kleiner DE, Hoofnagle JH, Robuck PR for the Nonalcoholic Steatohepatitis Clinical Research Network. Effects of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents. The TONIC randomized controlled trial. *JAMA* 2011; 305: 1659-1668.
28. Lazo M, Hernaez R, Bonekamp S, Kamel IR, Brancatti FL, Guallar E, Clark JM. Non-alcoholic fatty liver disease and mortality among US adults: a prospective cohort study. *BMJ* 2011; 343: d6891.
29. Leite NC, Villela-Nogueira CA, Pannain VLN, Bottino AC, Rezende GFM, Cardosos CRL, Salles GF. Histopathological stages of nonalcoholic fatty liver disease in type 2 diabetes: prevalences and correlated factors. *Liver Int* 2011; 31: 700-706.
30. Lorbeer R, Bayerl C, Auweter S, Rospleszcz S, Lieb W, Meisinger C, Heier M, Peters A, Bamberg F, Hetterich H. Association between MRI-derived hepatic fat fraction and blood pressure in participants without history of cardiovascular disease. *J Hypertens* 2017; 35: 737-744
31. Manco M, Marcellini M, DeVito R, Comparcola D, Sartorelli MR, Nobili V. Metabolic syndrome and liver histology in paediatric non-alcoholic steatohepatitis. *Int J Obes* 2008; 32: 381-387.
32. Miura K, Kodama Y, Inokuchi S, Schnabl B, Aoyama T, Ohnishi H, Olefsky JM, Brenner DA, Seki E. Toll-like receptor 9 promotes steatohepatitis by induction of interleukin-1beta in mice. *Gastroenterology* 2010; 139: 323-334.
33. Molloy JW, Calcagno CJ, Williams CD, Jones FJ, Torres DM, Harrison SA. Association of coffee and caffeine consumption with fatty liver disease, nonalcoholic steatohepatitis, and degree of hepatic fibrosis. *Hepatology* 2012; 55: 429-436
34. Mouzaki M, Comelli EM, Arendt BM, Bonengel J, Fung SK, Fischer SE, McGilvray ID, Allard JP. Intestinal microbiota in patients with nonalcoholic fatty liver disease. *Hepatology* 2013; 58: 120-127.

35. Mummadi RR, Kasturi KS, Chennareddygari S, Sood GK. Effect of bariatric surgery on nonalcoholic fatty liver disease: systematic review and meta-analysis. *Clin Gastroenterol Hepatol* 2008; 6: 1396-1402.
36. Musso G, Gambino R, Cassader M, Pagano G. A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease. *Hepatology* 2010; 52: 79-104
37. Nicholson JK, Holmes E, Kinross J, Burcelin R, Gibson G, Jia W, Pettersson S. Host-gut microbiota metabolic interactions. *Science* 2012; 336: 1262–1267.
38. Promrat K, Kleiner DE, Niemeier HM, Jackvony E, Kearns M, Wands JR, Fava JL, Wing RR. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. *Hepatology* 2010; 51: 121-129
39. Qin J1, Li R, Raes J, Arumugam M, Burgdorf KS, Manichanh C, Nielsen T, Pons N, Levenez F, Yamada T, Mende DR, Li J, Xu J, Li S, Li D, Cao J, Wang B, Liang H, Zheng H, Xie Y, Tap J, Lepage P, Bertalan M, Batto JM, Hansen T, Le Paslier D, Linneberg A, Nielsen HB, Pelletier E, Renault P, Sicheritz-Ponten T, Turner K, Zhu H, Yu C, Li S, Jian M, Zhou Y, Li Y, Zhang X, Li S, Qin N, Yang H, Wang J, Brunak S, Doré J, Guarner F, Kristiansen K, Pedersen O, Parkhill J, Weissenbach J; MetaHIT Consortium, Bork P, Ehrlich SD, Wang J. A human gut microbial gene catalogue established by metagenomic sequencing. *Nature* 2010; 464: 59-65.
40. Queipo-Ortuno MI, Boto-Ordonez M, Murri M, Gomez-Zumaquero JM, Clement-Postigo M, Estruch R, Diaz FC, Andres-Lacueva C, Tinahomes FJ. Influence of red wine polyphenols and ethanol on the gut microbiota ecology and biochemical biomarkers. *Am J Clin Nutr* 2012; 95: 1323-1334.
41. Ratziu V, Charlott F, Heurtier A, Gombert S, Giral P, Bruckert E, Grimaldi A, Capron F, Poynard T for the LIDO Study Group. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. *Gastroenterology* 2005; 128: 1898-1906.
42. Rhee EJ, Lee WY, Cho YK, Kim BI, Sung KC. Hyperinsulinemia and the development of nonalcoholic fatty liver disease in nondiabetic adults. *Am J Med* 2011; 124: 69-76.
43. Roeb E, Steffen HM, Bantel H, Baumann U, Canbay A, Demir M, Drebber U, Geier A, Hampe J, Hellerbrand C, Pathil-Warth A, Schattenberg JM, Schramm C, Seitz HK, Stefan N, Tacke F, Tannapfel A, Lynen Jansen P, Bojunga J. S2k-Leitlinie nicht-alkoholische Fettlebererkrankungen. *Z Gastroenterol* 2015; 53: 668-773
44. Salvi P, Ruffini R, Agnoletti D, Magnani E, Pagliarani G, Comandini G, Pratico A, Borghi C, Benetos A, Pazzi P. Increased arterial stiffness in nonalcoholic fatty liver disease: the Cardio-GOOSE study. *J Hypertens* 2010; 28: 1699-1707.

45. Sanyal AJ, Chalasani N, Kowdley KV, McCullough A, Diehl AM, Bass NM, Neuschwander-Tetri BA, Lavine JE, Tonascia J, Unalp A, van Natta M, Clark J, Brunt EM, Kleiner DE, Hoofnagle JH, Robuck PR for the NASH CRN. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. *N Engl J Med* 2010; 362: 1675-1685.
46. Schramm C, Dinter J, Demir M, Lengerli K, Töx U, Steffen HM. Hypertonie-Prävalenz und antihypertensive Behandlungsmodalitäten bei Patienten mit bioptisch gesicherter nicht-alkoholischer Fettlebererkrankung. *J Hyperton* 2010; 14: 21-25.
47. Schwimmer J, Deutsch R, Kahen T, Lavine JE, Stanley C, Behling C. Prevalence of fatty liver in children and adolescents. *Pediatrics* 2006; 118:1388-1393.
48. Shah AG, Lydecker A, Murray K, Tetri BN, Contos MJ, Sanyal AJ and NASH Clinical Research Network. Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease. *Clin Gastroenterol Hepatol* 2009; 7: 1104-1112.
49. Smith BW Adams LA. Nonalcoholic fatty liver disease and diabetes mellitus : pathogenesis and treatment. *Nat Rev Endocrinol* 2011; 7: 456-465.
50. Sookoian S, Pirola C. Non-alcoholic fatty liver disease is strongly associated with carotid atherosclerosis: A systematic review. *J Hepatol* 2008; 49:600-607.
51. Targher G, Day CP, Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. *N Engl J Med* 2010; 363: 1341-1350.
52. Targher G, Tessari R, Bertolini L, Zenari L, Padovani R, Day C, Rodella S, Arcardo G. Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients. *Diabetes Care* 2007; 30: 1212-1218.
53. Thoma C, Day CP, Trenell MI. Lifestyle interventions for the treatment of non-alcoholic fatty liver disease in adults : a systematic review. *J Hepatol* 2012; 56: 255-266.
54. Tilg H, Moschen AR. Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. *Hepatology* 2010; 52: 1836-1846.
55. Töx U, Steffen HM. Impact of inhibitors of the renin-angiotensin-aldosterone system on liver fibrosis and portal hypertension. *Curr Med Chem* 2006; 13: 3649-3661.
56. Vasunta RI, Kesäniemi YA, Ylitalo AS, Ukkola OH. High ambulatory blood pressure values associated with non-alcoholic fatty liver in middle-aged adults. *J Hypertens* 2012; 30: 2015-2019
57. Villanova N, Moscatiello S, Ramilli S, Bugianesi E, Magalotti D, Vanni E, Zoli M, Marchesini G. Endothelial dysfunction and cardiovascular risk profile in nonalcoholic fatty liver disease. *Hepatology* 2005; 42: 473-480.

58. Vlachopoulos C, Manesis E, Baou K, Papatheodoridis G, Koskinas J, Tiniakos D, Azanouridis K, Archimandritis A, Stefanidis C. Increased arterial stiffness and impaired endothelial function in nonalcoholic fatty liver disease : a pilot study. *Am J Hypertens* 2010; 23: 1183-1189.
59. Wang Z, Xiao G, Yao Y, Guo S, Lu K, Sheng Z. The role of bifidobacteria in gut barrier function after thermal injury in rats. *J Trauma* 2006; 61: 650-657.
60. Williams CD, Stengel J, Asike MI, Torres DM, Shaw J, Contreras M, Landt CL, Harrison SA. Prvalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy : a prospective study. *Gastroenterology* 2011; 140: 124-131.
61. Zelber-Sagi S, Nitzan-Kaluski D, Goldsmith R, Webb M, Zvibel I, Goldiner I, Blendis L, Halpern Z, Oren R. Role of leisure-time physical activity in nonalcoholic fatty liver disease: A population-based study. *Hepatology* 2008; 48: 1791-1798.